Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain
NCT ID: NCT00647127
Last Updated: 2012-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
22 participants
INTERVENTIONAL
2008-02-29
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Buprenorphine
Buprenorphine
Buprenorphine: 20microg/h
Fentanyl
Fentanyl
Fentanyl: 25microg/h
Placebo
Placebo
Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Buprenorphine
Buprenorphine: 20microg/h
Fentanyl
Fentanyl: 25microg/h
Placebo
Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* men \> 18 years
Exclusion Criteria
* known allergy against the investigated drugs
* ongoing participation in other experiments or participation in other experiments 14 days before screening
* previously pain or psychiatric conditions
* simultaneously use of pain killers
* alcohol
* previously drug-addict or member of family with drug-addicts
* chronic constipation
* ileus
* inflammatory bowel syndrome
* abdominal surgery within the last three months
18 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Asbjoern M Drewes, MD, Prof.
Role: PRINCIPAL_INVESTIGATOR
Mech Sense, Department of Gastroenterology, Aalborg Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mech Sense, Department of Gastroenterology
Aalborg, Region Nordjyllan, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-004524-21
Identifier Type: -
Identifier Source: org_study_id